Testing a new cell therapy for hard-to-treat blood cancers

Plain-English translation of NCT06765876 on ClinicalTrials.gov ↗ · Source last updated January 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new treatment called CART123, which uses your own immune cells to fight certain blood cancers that have come back or stopped responding to other treatments. Doctors will collect your T cells (a type of immune cell), modify them in a lab to recognize and attack cancer cells, and then put them back into your body. The study will gradually increase the dose to find the right amount that works best and is safest.

Many patients with hard-to-treat blood cancers like acute myeloid leukemia and myelodysplastic syndromes have run out of standard treatment options or their cancer has come back despite previous therapy. This medication represents a new approach using the body's own immune system to fight these serious diseases.

Do you qualify?

You likely qualify if…

you have been diagnosed with one of these specific blood cancers (acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or blastic plasmacytoid dendritic cell cancer) and your cancer either didn't respond to treatment or has come back
your cancer cells test positive for a marker called CD123
you are between 18 and 70 years old
you have a matched stem cell donor available and that donor has been approved by a transplant center (in case you need a stem cell transplant later)
you have no other standard treatment options available or have already tried all available options
you are able to understand and sign the informed consent form

You likely don't qualify if…

you have had a stem cell transplant in the past 3 months
you have a serious active infection that is not controlled
you have significant liver or kidney disease, or heart failure with reduced function
you are pregnant, breastfeeding, or not willing to use effective birth control during the study
you have received a live virus vaccine in the past 4 weeks

What participation looks like

First, your stem cells will be collected and sent to a lab where they're modified to create the new therapy. You'll then receive chemotherapy to prepare your body, followed by a single infusion of the modified cells. Because this is an early-stage trial testing different doses, you'll be closely monitored with frequent blood tests and visits to watch for how well the treatment works and to catch any side effects early. The study team will also discuss with you whether a stem cell transplant might be needed as a backup option.

AI-generated summary from trial data · Jun 15, 2026 · Not medical advice

Testing a new cell therapy for hard-to-treat blood cancers

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)